Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Solomon Epstein

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Annals of the New York Academy of Sciences|December 7, 2007
Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonatesMone Zaidi, Solomon Epstein, Steven T Harris, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|August 17, 2005
Bone metabolism in renal transplant patients treated with cyclosporine or sirolimusJosep M Campistol, David W Holt, Solomon Epstein, et al.
Diabetes Care|January 23, 2016
The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification SchemaStanley S Schwartz, Solomon Epstein, Barbara E Corkey, et al.
Trends in Endocrinology and Metabolism: TEM|June 21, 2017
A Unified Pathophysiological Construct of Diabetes and its ComplicationsStanley S Schwartz, Solomon Epstein, Barbara E Corkey, et al.
Current Osteoporosis Reports|December 9, 2009
Bone loss or lost bone: rationale and recommendations for the diagnosis and treatment of early postmenopausal bone lossMone Zaidi, Charles H Turner, Ernesto Canalis, et al.
American Journal of Physiology. Renal Physiology|September 14, 2006
Evidence that calcineurin is required for the genesis of bone-resorbing osteoclastsLi Sun, Yuanzhen Peng, Neeha Zaidi, et al.
Clinical Therapeutics|May 19, 2009
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) studyRonald Emkey, Pierre D Delmas, Michael Bolognese, et al.
American Journal of Physiology. Renal Physiology|November 7, 2002
Molecular cloning, expression, and function of osteoclastic calcineurin AalphaLi Sun, Baljit S Moonga, Min Lu, et al.
Annals of the New York Academy of Sciences|September 18, 2007
Cellular and molecular consequences of calcineurin A alpha gene deletionLi Sun, Ling-Ling Zhu, Neeha Zaidi, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 16, 2005
Calcineurin regulates bone formation by the osteoblastLi Sun, Harry C Blair, Yuanzhen Peng, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Annals of the New York Academy of Sciences|December 7, 2007
Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonatesMone Zaidi, Solomon Epstein, Steven T Harris, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|August 17, 2005
Bone metabolism in renal transplant patients treated with cyclosporine or sirolimusJosep M Campistol, David W Holt, Solomon Epstein, et al.
Diabetes Care|January 23, 2016
The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification SchemaStanley S Schwartz, Solomon Epstein, Barbara E Corkey, et al.
Trends in Endocrinology and Metabolism: TEM|June 21, 2017
A Unified Pathophysiological Construct of Diabetes and its ComplicationsStanley S Schwartz, Solomon Epstein, Barbara E Corkey, et al.
Current Osteoporosis Reports|December 9, 2009
Bone loss or lost bone: rationale and recommendations for the diagnosis and treatment of early postmenopausal bone lossMone Zaidi, Charles H Turner, Ernesto Canalis, et al.
American Journal of Physiology. Renal Physiology|September 14, 2006
Evidence that calcineurin is required for the genesis of bone-resorbing osteoclastsLi Sun, Yuanzhen Peng, Neeha Zaidi, et al.
Clinical Therapeutics|May 19, 2009
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) studyRonald Emkey, Pierre D Delmas, Michael Bolognese, et al.
American Journal of Physiology. Renal Physiology|November 7, 2002
Molecular cloning, expression, and function of osteoclastic calcineurin AalphaLi Sun, Baljit S Moonga, Min Lu, et al.
Annals of the New York Academy of Sciences|September 18, 2007
Cellular and molecular consequences of calcineurin A alpha gene deletionLi Sun, Ling-Ling Zhu, Neeha Zaidi, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 16, 2005
Calcineurin regulates bone formation by the osteoblastLi Sun, Harry C Blair, Yuanzhen Peng, et al.
Pageof 3